JP2007063288A5 - - Google Patents

Download PDF

Info

Publication number
JP2007063288A5
JP2007063288A5 JP2006302712A JP2006302712A JP2007063288A5 JP 2007063288 A5 JP2007063288 A5 JP 2007063288A5 JP 2006302712 A JP2006302712 A JP 2006302712A JP 2006302712 A JP2006302712 A JP 2006302712A JP 2007063288 A5 JP2007063288 A5 JP 2007063288A5
Authority
JP
Japan
Prior art keywords
alkylene
pharmaceutical composition
lower alkyl
aryl
composition according
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2006302712A
Other languages
English (en)
Japanese (ja)
Other versions
JP2007063288A (ja
Filing date
Publication date
Application filed filed Critical
Publication of JP2007063288A publication Critical patent/JP2007063288A/ja
Publication of JP2007063288A5 publication Critical patent/JP2007063288A5/ja
Pending legal-status Critical Current

Links

JP2006302712A 2000-08-07 2006-11-08 エンドセリンアンタゴニストを用いる癌及び癌関連痛の治療方法 Pending JP2007063288A (ja)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US63338900A 2000-08-07 2000-08-07

Related Parent Applications (1)

Application Number Title Priority Date Filing Date
JP2002517050A Division JP4217068B2 (ja) 2000-08-07 2001-08-06 エンドセリンアンタゴニストを用いる癌及び癌関連痛の治療方法

Publications (2)

Publication Number Publication Date
JP2007063288A JP2007063288A (ja) 2007-03-15
JP2007063288A5 true JP2007063288A5 (cg-RX-API-DMAC10.html) 2008-07-31

Family

ID=24539436

Family Applications (3)

Application Number Title Priority Date Filing Date
JP2002517050A Expired - Fee Related JP4217068B2 (ja) 2000-08-07 2001-08-06 エンドセリンアンタゴニストを用いる癌及び癌関連痛の治療方法
JP2006302713A Pending JP2007084564A (ja) 2000-08-07 2006-11-08 エンドセリンアンタゴニストを用いる癌及び癌関連痛の治療方法
JP2006302712A Pending JP2007063288A (ja) 2000-08-07 2006-11-08 エンドセリンアンタゴニストを用いる癌及び癌関連痛の治療方法

Family Applications Before (2)

Application Number Title Priority Date Filing Date
JP2002517050A Expired - Fee Related JP4217068B2 (ja) 2000-08-07 2001-08-06 エンドセリンアンタゴニストを用いる癌及び癌関連痛の治療方法
JP2006302713A Pending JP2007084564A (ja) 2000-08-07 2006-11-08 エンドセリンアンタゴニストを用いる癌及び癌関連痛の治療方法

Country Status (22)

Country Link
EP (1) EP1347751B1 (cg-RX-API-DMAC10.html)
JP (3) JP4217068B2 (cg-RX-API-DMAC10.html)
KR (1) KR20030027007A (cg-RX-API-DMAC10.html)
CN (1) CN1635878A (cg-RX-API-DMAC10.html)
AR (1) AR031122A1 (cg-RX-API-DMAC10.html)
AT (1) ATE465728T1 (cg-RX-API-DMAC10.html)
AU (2) AU8113401A (cg-RX-API-DMAC10.html)
BG (1) BG107577A (cg-RX-API-DMAC10.html)
BR (1) BR0108865A (cg-RX-API-DMAC10.html)
CA (1) CA2416879C (cg-RX-API-DMAC10.html)
DE (1) DE60141979D1 (cg-RX-API-DMAC10.html)
HU (1) HUP0302977A2 (cg-RX-API-DMAC10.html)
IL (1) IL153769A0 (cg-RX-API-DMAC10.html)
MX (1) MXPA03000984A (cg-RX-API-DMAC10.html)
NO (1) NO20030593L (cg-RX-API-DMAC10.html)
NZ (1) NZ523562A (cg-RX-API-DMAC10.html)
PE (1) PE20020273A1 (cg-RX-API-DMAC10.html)
PL (1) PL366160A1 (cg-RX-API-DMAC10.html)
SK (1) SK1782003A3 (cg-RX-API-DMAC10.html)
TW (1) TWI306760B (cg-RX-API-DMAC10.html)
WO (1) WO2002011713A2 (cg-RX-API-DMAC10.html)
ZA (1) ZA200300253B (cg-RX-API-DMAC10.html)

Families Citing this family (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB0219660D0 (en) 2002-08-23 2002-10-02 Astrazeneca Ab Therapeutic use
GB0403744D0 (en) 2004-02-20 2004-03-24 Astrazeneca Ab Chemical process
CN101022826A (zh) * 2004-06-07 2007-08-22 哈罗尔·戴维·贡 用于癌症治疗的细菌组合物
US9107864B2 (en) 2004-06-07 2015-08-18 Qu Biologics Inc. Tissue targeted antigenic activation of the immune response to treat cancers
CA2697057A1 (en) 2007-08-22 2009-02-26 Gilead Colorado, Inc. Therapy for complications of diabetes
WO2011114103A1 (en) 2010-03-18 2011-09-22 Biolipox Ab Pyrimidinones for use as medicaments
PL2598165T3 (pl) 2010-07-26 2018-02-28 Qu Biologics Inc. Immunogenne kompozycje przeciwzapalne
CN102485238A (zh) * 2010-12-06 2012-06-06 陈炯华 芎芷镇痛方
CN106456740B (zh) 2014-05-02 2021-06-08 Qu生物制药公司 抗微生物免疫调节

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6063911A (en) * 1993-12-01 2000-05-16 Marine Polymer Technologies, Inc. Methods and compositions for treatment of cell proliferative disorders
ES2259803T3 (es) * 1996-02-13 2006-10-16 Abbott Laboratories Nuevos derivados de pirrolidina sustituidos con benzo-1,3-dioxolilo y benzofuranilo como antagonistas de endostelina.
HUP0003484A3 (en) 1997-08-04 2002-02-28 Abbott Lab Pyrrolidine-3-crboxylic acid derivatives and their use as endothelin antagonists
WO2000036198A1 (en) * 1998-12-11 2000-06-22 Mactapes Limited Curtain heading tape manufacture
US6545048B1 (en) * 1999-06-29 2003-04-08 California Institute Of Technology Compositions and methods of treating cancer using compositions comprising an inhibitor or endothelin receptor activity

Similar Documents

Publication Publication Date Title
JP5576591B2 (ja) α,α,α−トリフルオロチミジンとチミジンホスホリラーゼ阻害剤とを配合した抗癌剤
KR100956195B1 (ko) 인 함유 화합물 및 이의 용도
US12128048B2 (en) Combination therapies using PRMT5 inhibitors for the treatment of cancer
JP2002519434A5 (cg-RX-API-DMAC10.html)
KR20150018809A (ko) 핵 수송 조절인자 및 이의 용도
EP1240174A2 (en) Novel bisamidate phosphonate prodrugs
JP2006507220A5 (cg-RX-API-DMAC10.html)
JP2008505902A5 (cg-RX-API-DMAC10.html)
HRP20100366T1 (hr) Antagonisti receptora progesterona
JP2003502405A5 (cg-RX-API-DMAC10.html)
CA3214535A1 (en) Combination therapies using prmt5 inhibitors for the treatment of cancer
JP2014530191A5 (cg-RX-API-DMAC10.html)
JP2008535803A5 (cg-RX-API-DMAC10.html)
JP2002519425A5 (cg-RX-API-DMAC10.html)
JP2006518731A5 (cg-RX-API-DMAC10.html)
JP2007084564A5 (cg-RX-API-DMAC10.html)
JP2006501306A5 (cg-RX-API-DMAC10.html)
JP2008510758A5 (cg-RX-API-DMAC10.html)
US9457018B2 (en) Method for combating adverse effects arising from antipsychotic treatment
RU2005128831A (ru) Обладающие противоопухолевым действием 2-замещенные эстра-1,3,5( 10 )-триен-3-илсульфаматы
AU2003232805A8 (en) Pharmaceutical active substance combination and the use thereof
WO2023059795A1 (en) Combination therapies using prmt5 inhibitors for the treatment of cancer
JP2013523867A5 (cg-RX-API-DMAC10.html)
JP2010528088A5 (cg-RX-API-DMAC10.html)
MX2009006635A (es) Compuestos de imidazolidinonil aminopirimidina para el tratamiento de cancer.